USFDA issues zero observations for Gland Pharma Visakhapatnam API facility
Visakhapatnam: Gland Pharma has recently announced that the company has received zero observations from the US Food and Drug Administration (USFDA) after an inspection at the company's API Facility at JNPC, Visakhapatnam.The inspection was conducted from 23rd January, 2023 to 27th January, 2023."We wish to inform you that the United States Food and Drug Administration (US FDA)...
Visakhapatnam: Gland Pharma has recently announced that the company has received zero observations from the US Food and Drug Administration (USFDA) after an inspection at the company's API Facility at JNPC, Visakhapatnam.
The inspection was conducted from 23rd January, 2023 to 27th January, 2023.
"We wish to inform you that the United States Food and Drug Administration (US FDA) conducted an inspection at the Company’s API Facility at JNPC, Visakhapatnam from 23rd January, 2023 to 27th January, 2023, and has been completed with Zero observations," Gland Pharma informed in a BSE filing.
Read also: Gland Pharma net profit declines 15 percent to Rs 232 crore in Q3
Gland Pharma, a generic injectable-focused pharmaceutical company was established in 1978 in Hyderabad. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.
Read also: Gland Pharma gets UFSDA EIR for Dundigal Facility
